Fundz

EG 427 raised €27 million in a Series B funding round co-led by Andera Partners and Bpifrance to advance clinical trials for genetic medicine solutions targeting chronic neurological diseases.

PRIVATEFeb 20, 2025

Amount Raised

€27 Million

Round Type

Series B

Biotechnology

Investors

SCI VenturesAndera PartnersBpifrance

Description

EG 427, a Paris-based BioTech startup, announced the successful closing of a €27 million Series B financing round. The funding will support the development of innovative genetic medicine solutions addressing underserved pathologies in neuro-urology, particularly in bladder dysfunction.

Quick answer

EG 427 raised €27 Million in a Series B round, dated February 20, 2025. Investors: SCI Ventures, Andera Partners and Bpifrance.

How much did EG 427 raise?
EG 427 raised €27 Million in a Series B round on February 20, 2025.
Who invested in EG 427?
SCI Ventures, Andera Partners and Bpifrance are named as investors in this round.
What does EG 427 do?
At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the..
Where is EG 427 based and how big is it?
Fundz records about 23 employees.
Who are the decision-makers at EG 427?
Fundz holds 1 contact at EG 427. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as EG 427 that raised within 45 days of this round, from Fundz verified event records.

  • Treysta Medical Technologies raised $93K (Pre-Seed) on April 4, 2025.
  • Astek Diagnostics raised $750K (Series A) on April 4, 2025.
  • Exobiosphere raised $2.2M (Seed) on April 4, 2025.
  • RayThera raised $110M (Series A) on April 4, 2025.
  • FOXO Technologies raised $325K (Seed) on April 4, 2025.
  • Perkant Tech raised $772K (Seed) on April 3, 2025.

Who to call at EG 427, and when

A new round usually means EG 427 is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day EG 427 raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at EG 427, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at EG 427. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

EG 427

About

At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, is expected to be in the clinic by early 2024. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment EG 427 raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for EG 427's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

EG 427 raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.